MOR106 is the first publicly disclosed human monoclonal antibody designed to selectively target IL-17C in clinical development worldwide. It has been shown to inhibit potently the binding of IL-17C to its receptor and thus to inhibit its biological activity.
Galapagos and MorphoSys announced positive topline results in a Ph1b study with MOR106 in patients with moderate-to-severe atopic dermatitis in September 2017. In 2018 Galapagos and MorphoSys announced the start of the IGUANA Phase 2 trial, and in 2019 the companies announced the start of the GECKO Phase 2 trial with MOR106 in patients with moderate to severe atopic dermatitis.
MOR106 arose from a strategic discovery and co-development alliance between Galapagos and MorphoSys. Galapagos provides the disease-related biology including cellular assays and targets discovered using its target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound. In July 2018, Galapagos and MorphoSys announced a global collaboration with Novartis to develop MOR106 further in atopic dermatitis and potentially other indications.
Blocking IL-17C reverses the disease signature in a mouse model of atopic dermatitis, World Congress of Inflammation, July 2017
IL-17C inhibition reduces skin inflammation in a mouse IL-23-induced psoriasis model, ESDR September 2017